NCT02960282
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting

Drug Category: Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are eligible for cohort B
Exclusions: Patients not eligible to receive Keytruda/pembrolizumab or another anti-PD-1 or anti-PD-L1 antibody (e.g. Tecentriq/atezolizumab) as single agent treatment for the metastatic disease
https://ClinicalTrials.gov/show/NCT02960282